Tetracyclines for multidrug-resistant Acinetobacter baumannii infections

Area of Science:

• Infectious Diseases
• Clinical Pharmacology
• Bacteriology

Background:

• Multidrug-resistant Acinetobacter baumannii poses a significant global health threat.
• Limited development of novel antimicrobial agents necessitates re-evaluation of older antibiotics.
• Tetracyclines represent a class of older antibiotics with potential utility against resistant bacteria.

Purpose of the Study:

• To systematically review existing clinical evidence on the efficacy and safety of tetracyclines for treating Acinetobacter baumannii infections.
• To assess the outcomes of doxycycline and minocycline in a real-world clinical setting.
• To identify the role of tetracyclines in the management of multidrug-resistant Acinetobacter baumannii.

Main Methods:

• Systematic review of ten retrospective studies.
• Inclusion of data from 156 patients with 185 Acinetobacter baumannii infections.
• Analysis of clinical success, microbiological eradication, and adverse events associated with tetracycline use.

Main Results:

• Clinical success was observed in 76.9% of patients, with higher rates in bloodstream infections (87.5%) compared to respiratory infections (71.9%).
• Microbiological eradication was achieved in 71.3% of cases.
• Tetracycline regimens, often used in combination therapy, were associated with a low incidence of adverse events (1.1%).

Conclusions:

• Tetracycline-containing regimens demonstrate encouraging clinical outcomes for Acinetobacter baumannii infections, including MDR strains.
• The findings suggest a potential role for tetracyclines in treating challenging Acinetobacter baumannii infections.
• Larger, comparative clinical trials are essential to definitively establish the place of tetracyclines in the treatment guidelines for multidrug-resistant Acinetobacter baumannii.